{
    "id": 29006,
    "fullName": "NTRK1 A608D",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NTRK1 A608D lies within the protein kinase domain of the Ntrk1 protein (UniProt.org). A608D has been demonstrated to promote secondary drug resistance in the context of CTRC-NTRK1 (PMID: 29466156), but has not been biochemically characterized and therefore, its effect on Ntrk1 protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4914,
        "geneSymbol": "NTRK1",
        "terms": [
            "NTRK1",
            "MTC",
            "p140-TrkA",
            "TRK",
            "Trk-A",
            "TRK1",
            "TRKA"
        ]
    },
    "variant": "A608D",
    "createDate": "11/27/2018",
    "updateDate": "11/03/2019",
    "referenceTranscriptCoordinates": {
        "id": 177644,
        "transcript": "NM_002529",
        "gDna": "chr1:g.156879139C>A",
        "cDna": "c.1823C>A",
        "protein": "p.A608D",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15270,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, NTRK1 A608D was identified at disease progression in a patient with pancreatic cancer harboring CTRC-NTRK1 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30931,
                "profileName": "CTRC - NTRK1 NTRK1 A608D"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30929,
            "profileName": "NTRK1 A608D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30931,
            "profileName": "CTRC - NTRK1 NTRK1 A608D",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 177644,
            "transcript": "NM_002529",
            "gDna": "chr1:g.156879139C>A",
            "cDna": "c.1823C>A",
            "protein": "p.A608D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}